Arizona Tribune - DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2

KELOWNA, BC / ACCESS Newswire / August 24, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that blood plasma pharmacokinetic ("PK") bioanalysis testing has been completed in its 2026 Animal Study #2 (GLP-1-A26-2, the "Study"). The Study examined oral delivery of 2 next-generation glucagon-like peptide-1 ("GLP-1") drugs, amycretin and retatrutide, in a total of 18 different study arms in dogs following formulation and processing using Lexaria's patented DehydraTECH^TM ("DHT") drug delivery enabling platform technology formulated in oral tablet and capsule formats.

The Study utilized both Lexaria's DehydraTECH-GLP-1 2.0 ("DHT2.0") formulation tested against Lexaria's new DehydraTECH-GLP-1 3.0 ("DHT3.0") formulations together with potentially complementary commercially available gastrointestinal absorption enhancer compounds; salcaprozate sodium ("SNAC") or sodium caprate. Lexaria is testing DHT3.0 formulations in anticipation of supporting existing and future business development initiatives for the next generation of GLP-1 drugs under development around the world.

"Lexaria never stops innovating in our pursuit of the most effective oral drug delivery possible," said Richard Christopher, CEO of Lexaria. "Not only are our latest enhancements producing clear improvements in performance over earlier versions of DehydraTECH, but those improvements demonstrate our rapidly growing understanding of the interactions between DehydraTECH and the next generation of GLP-1 drugs."

AMYCRETIN

AUC D = Dose normalized area under the curve, or total drug absorption measured over the course of the Study relative to the dose administered.

N/A = Not applicable because the REF DHT2.0 Capsule did not provide meaningful absorption data.

All data has been rounded to 2 decimal points for consistency and ease of presentation.

Lexaria's DHT3.0-amycretin tablet ("ALT 2 DHT3.0 Tablet") was the strongest DHT performer tested evidencing a 481.14% increase in bioavailability compared to the amycretin reference tablet ("REF DHT2.0 Tablet") that used DHT2.0 and SNAC. The patented DHT3.0 technology performed better with the 'open source' sodium caprate than it did with the SNAC technology currently used in Novo Nordisk's® oral Rybelsus® and Wegovy® tablet products.

All 3 of the DHT3.0-amycretin tablet variations achieved superior absorption than the amycretin reference tablet ("REF DHT2.0 Tablet") that used DHT2.0 and SNAC. Lexaria considers these improvements in DHT3.0 performance to be deeply meaningful relative to our ultimate goal of attracting widespread adoption of DHT technology within the multi-billion-dollar GLP-1 sector and its next-generation drugs. If confirmed with further testing including human studies, DHT3.0 GLP-1 formulations could eventually be of interest to pharmaceutical companies working towards adoption of their own proprietary weight loss drugs.

Lexaria's best performing DHT-amycretin tablet formulation ("ALT 2 DHT3.0 Tablet"), rendered in a 4 mg oral tablet format, evidenced a 136%, or more than double, increase in absolute bioavailability (1.65%) compared to animal research published by Novo Nordisk A/S that indicated an absolute bioavailability level of 0.70% for its SNAC-inclusive orally administered amycretin at comparable dosing, but without DHT, in primates. Lexaria acknowledges, however, that inter-species variability between the two different studies likely contributed to some unknown degree to the difference in those outcomes.

The amycretin reference capsule ("REF DHT2.0 Capsule") did not provide meaningful absorption data relative to the lower limit of detection of the bioassay utilized for this Study, so no comparisons can be made between it and the DHT3.0 capsule variations in the Study.

RETATRUTIDE

All 3 of the 3 experimental DHT3.0-retatrutide capsule formulations, and all 3 of the 3 experimental DHT3.0-retatrutide tablet formulations, outperformed the respective retatrutide reference capsules and tablets enabled with DHT2.0 and SNAC.

AUC D = Dose normalized area under the curve, or total drug absorption measured over the course of the Study relative to the dose administered.

All data has been rounded to 2 decimal points for consistency and ease of presentation.

The 3 various DHT3.0-retatrutide tablet formulations showed astonishing improvements in absorption of roughly 5x to 46x that of the reference tablets ("REF DHT2.0 Tablet"), which was highlighted by an astonishing 4,552.20% improvement in absorption in the best performing DHT-retatrutide tablet formulation ("ALT 2 DHT3.0 Tablet") as compared to the retatrutide reference tablets ("REF DHT2.0 Tablet"). Consistent with the amycretin results in the Study, retatrutide with the patented DHT3.0 technology performed better with the 'open source' sodium caprate than it did with the SNAC technology currently used in Novo Nordisk's® oral Rybelsus® and Wegovy® tablet products. It is not known at this time whether these improvements are a function of the relatively low absorption of the retatrutide reference tablets, or are indeed representative of reproducible results. Taken at face value, the significant improvements in absorption utilizing DHT3.0 processing and formulation improvements certainly suggest that an oral version of the presently injection-only drug retatrutide may indeed be possible, although extensive human studies would be required to fully validate this.

Bioanalytical testing with the best performing DHT3.0-retatrutide capsule formulations ("ALT 1 DHT3.0 Capsule" and "ALT 2 DHT3.0 Capsule") in the Study, rendered in a 7 mg oral capsule format, demonstrated absolute bioavailability at 0.26% relative to intravenously administered retatrutide ("Pure API (I.V.))". Lexaria has been unable to source any published scientific literature for comparison purposes for other oral developmental formulations of retatrutide and notes that absolute bioavailability of the only commercially available, oral GLP-1 peptide, semaglutide, can be as low as 0.33-0.63% in dogs in published animal study findings at similar dosing levels, or as low as 0.4-1.0% in its initially launched Rybelsus® "R1" composition in humans. Retatrutide, however, lacks similar published references. Relatively speaking, Lexaria's DehydraTECH-retatrutide oral absolute bioavailability finding of 0.26% appears to show directional positivity worthy of further research and development enhancement and exploration.

About the Study and Absolute Bioavailability

The primary goals of this Study were to investigate compatibility of amycretin and retatrutide with Lexaria's DHT-3.0 formulation and processing technology together with certain potentially complementary commercially available gastrointestinal absorption enhancer compounds, centered around PK performance and tolerability. Blood samples were taken at multiple timepoints over a 24-hour post-dosing period to quantify the PK performance of each composition. There were a total of 9 study arms for each of amycretin and retatrutide, including 1 intravenous arm each to provide 100% absolute bioavailability benchmarks; as well as 1 reference DHT2.0 tablet and 1 reference DHT2.0 capsule for each of the drugs: allowing for 3 experimental DHT3.0 capsule and 3 experimental DHT3.0 tablet-related arms for each drug.

Absolute bioavailability is the fraction of an active drug substance that reaches the systemic circulation following non-intravenous administration compared to an intravenous given dose. This figure is noteworthy particularly when compared to available published scientific literature.

As in Animal Study #1 (GLP-1-A26-1) announced on April 15th, this Study also evaluated alternative DHT formulations to those previously explored or commercially available. The present Study included 1 capsule and 1 tablet composition for each of amycretin and retatrutide using sodium caprate which has itself been shown to influence gastrointestinal absorption.

Retatrutide is owned by Eli Lilly and Company®, whereas amycretin is owned by Novo Nordisk®, and are two of the most powerful, next generation GLP-1 peptide drugs under pre-commercial development in the world today, presently in advanced clinical testing only in injectable formats despite increasing consumer interest and demand for oral GLP-1 therapies.

Additional Study information including tolerability and other data will be released in due course upon completion of all relevant analysis and reporting. This was a self-sponsored Lexaria Study that was fully funded from existing corporate resources.

About Lexaria Bioscience Corp. & DehydraTECH^TM

DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH^TM has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 66 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH^TM technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
[email protected]
Phone: 250-765-6424, ext 202

SOURCE: Lexaria Bioscience Corp.

View the original press release on ACCESS Newswire

E.Hall--AT